FEDERAL RETIREMENT THRIFT INVESTMENT BOARD

Sunshine Act; Notice of Meeting

TIME AND DATE: 10 a.m. (Eastern Time), June 21, 2010.

PLACE: 4th Floor Conference Room, 1250 H Street, NW., Washington, DC 20005.

STATUS: Open to the public.

MATTERS TO BE CONSIDERED: 1. Approval of the minutes of the May 17, 2010 Board member meeting.

2. Thrift Savings Plan activity report by the Executive Director.

a. Monthly Participant Activity Report.

b. Monthly Investment Performance Review.

c. Legislative Report.

CONTACT PERSON FOR MORE INFORMATION: Thomas J. Trabucco, Director, Office of External Affairs, (202) 942–1640.

Dated: June 11, 2010.

Megan G. Grumbine,

Secretary (Acting), Federal Retirement Thrift Investment Board.

[FR Doc. 2010–14523 Filed 6–11–10; 4:15 pm]

BILLING CODE 6760–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the National Coordinator for Health Information Technology; HIT Policy Committee's Privacy & Security Tiger Team Meeting; Notice of Meeting

AGENCY: Office of the National Coordinator for Health Information Technology, HHS.

ACTION: Notice of meeting.

This notice announces a forthcoming subcommittee meeting of a Federal advisory committee of the Office of the National Coordinator for Health Information Technology (ONC). The meeting will be open to the public.

Name of Committee: HIT Policy Committee's Privacy & Security Tiger Team.

General Function of the Committee: To provide recommendations to the National Coordinator on a policy framework for the development and adoption of a nationwide health information technology infrastructure that permits the electronic exchange and use of health information as is consistent with the Federal Health IT Strategic Plan and that includes recommendations on the areas in which standards, implementation specifications, and certification criteria are needed.

Date and Time: The meeting will be held on June 29, 2010, from 8 a.m. to 5:15 p.m./ Eastern Time.

Location: Grand Hyatt Washington Hotel, 1000 H Street, NW., Washington, DC 20001 (telephone: 202–582–1234). Please check the ONC Web site, *http://healthit.hhs.gov,* for additional information as it becomes available, instructions on how to listen via telephone or Web, and viewing a video recording of the event which will be available following the meeting.

Contact Person: Judy Sparrow, Office of the National Coordinator, HHS, 330 C Street, SW., Washington, DC 20201, 202–205–4528, Fax: 202–690–6079, e-mail: *judy.sparrow@hhs.gov.* Please call the contact person for up-to-date information on this meeting. A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.

Agenda: The workgroup will be discussing technologies that enable consumer choice for sharing their information in health information exchange. The workgroup will be hearing testimony from current users of such technologies, developers of "cutting edge" technologies that may be useful in the clinical care setting in the future, as well as stakeholder groups. ONC intends to make background material available to the public no later than two (2) business days prior to the meeting. If ONC is unable to post the background material on its Web site prior to the meeting, it will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on ONC's Web site after the meeting, at *http://healthit.hhs.gov.*

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before June 23, 2010. Oral comments from the public will be scheduled between approximately 5 p.m. and 5:15 p.m./Eastern Time. Time allotted for each presentation will be limited to three minutes. If the number of speakers requesting to comment is greater than can be reasonably accommodated during the scheduled open public hearing session, ONC will take written comments after the meeting until close of business on that day.

Persons attending advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

ONC welcomes the attendance of the public at its advisory committee meetings. Web registration is highly recommended and is available at *http://www.blsmeetings.net/consumerchoicetechnologyhearing.* Seating is limited at the location, and ONC will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Judy Sparrow at least seven (7) days in advance of the meeting.

ONC is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at *http://healthit.hhs.gov* for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (Pub. L. 92–463, 5 U.S.C., App. 2).

Dated: June 9, 2010.

Judith Sparrow,

Office of Programs and Policy, Office of the National Coordinator for Health Information Technology.

[FR Doc. 2010–14395 Filed 6–14–10; 8:45 am]

BILLING CODE 4150–45–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2010–N–0121]

Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; The Mammography Quality Standards Act Requirements

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by July 15, 2010.

ADDRESSES: To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs, OMB, Attn: FDA Desk Officer, FAX: 202–395–7285, or e-mailed to *oira_submission@omb.eop.gov.* All comments should be identified with the OMB control number 0910–0309. Also include the FDA docket number found in brackets in the heading of this document.

FOR FURTHER INFORMATION CONTACT: Daniel Gittleson, Office of Information Management, Food and Drug Administration, 1350 Piccard Dr., PI50–400B, Rockville, MD 20850, 301–796–5156, *Daniel.Gittleson@fda.hhs.gov.*

SUPPLEMENTARY INFORMATION: In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.

The Mammography Quality Standards Act Requirements—21 CFR Part 900 (OMB Control Number 0910–0309)—Extension

The Mammography Quality Standards Act requires the establishment of a Federal certification and inspection program for mammography facilities;

regulations and standards for accreditation and certification bodies for mammography facilities; and standards for mammography equipment, personnel, and practices, including quality assurance. The intent of these regulations is to assure safe, reliable, and accurate mammography on a nationwide level. Under the regulations, as a first step in becoming certified, mammography facilities must become accredited by an FDA-approved accreditation body. This requires undergoing a review of their clinical images and providing the accreditation body with information showing that they meet the equipment, personnel, quality assurance and quality control standards, and have a medical reporting and recordkeeping program, a medical outcomes audit program, and a consumer compliant mechanism. On the basis of this accreditation, facilities are then certified by FDA or an FDA approved State certification agency and must prominently display their certificate. These actions are taken to ensure safe, accurate, and reliable mammography on a nationwide basis. The following sections of title 21 of the Code of Federal Regulations (CFR) were not included in the previously mentioned burden tables because they were considered usual and customary practice and were part of the standard of care prior to the implementation of the regulations. Therefore, they resulted in no additional reporting or recordkeeping burden: 21 CFR 900.12(c)(1) and (c)(3) and 21 CFR 900.3(f)(1). Section 900.3(c) was not included in the previously mentioned burden tables because all four existing accreditation bodies are approved until late in 2013; so, no applicants will reapply during the requested information collection period. Section 900.24(c) was also not included in the previously mentioned burden tables because if a certifying state had its approval withdrawn, FDA would take over certifying authority for the affected facilities. Because FDA already has all the certifying state's electronic records, there wouldn't be an additional reporting burden.

In the **Federal Register** of March 11, 2010 (75 FR 11542), FDA published a 60-day notice requesting public comment on the proposed collection of information. No comments were received.

FDA estimates the burden of this collection of information as follows:

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN

21 CFR Section	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours	Total Capital Costs	Total Operating & Maintenance Costs
900.3(b)(1)	0.33	1	0.33	1	0.33		
900.3(b)(3) full[1]	0.33	1	0.33	320	106	$10,000	
900.3(b)(3) limited[2]	5	1	5	30	150		
900.3(c)[3]	1.33	1	1.33	15	20		
900.3(d)(2)	0.1	1	0.1	30	3		
900.3(d)(5)	0.1	1	0.1	30	3		
900.3(e)	0.1	1	0.1	1	0.1		
900.3(f)(2)	0.1	1	0.1	200	20		$45
900.4(c), 900.11(b)(1), and 900.11(b)(2) facility[4]	2,894	1	2,894	1.5	4,341		
900.4(c) AB[5]	5	1	5	421	2,105		$173,620
900.4(d), 900.11(b)(1), and 900.11(b)(2) facility[4]	2,894	1	2,894	.75	2,171		
900.4(d) AB[5]	5	1	5	211	1,055		
900.4(e), 900.11(b)(1), and 900.11(b)(2) facility[4]	8,681	1	8,681	1	8,681		$8,681
900.4(e) AB[5]	5	1	5	1,736	8,680		

TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN—Continued

21 CFR Section	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours	Total Capital Costs	Total Operating & Maintenance Costs
900.4(f)	331	1	331	7	2,317		$77,640
900.4(h) facility[4]	8,681	1	8,681	1	8,681		$3,820
900.4(h) AB[5]	5	1	5	10	50		
900.4(i)(2)	1	1	1	16	16		
900.6(c)(1)	0.1	1	0.1	60	6		
900.11(b)(3)	5	1	5	.5	2.5		
900.11(c)	400	1	400	5	2,000		
900.12(c)(2)	8,681	4,942	42,901,502	.0833333	3,575,124		$19,500,000
900.12(c)(2) patient refusal[6]	87	1	87	.5	43.5		
900.12(h)(4)	7	1	7	1	7		
900.12(j)(1) facility[4]	8	1	8	200	1,600		$120
900.12(j)(1) AB[5]	8	1	8	320	2,560		$240
900.12(j)(2)	2	1	2	100	200		$3,875
900.15(c)	5	1	5	2	10		
900.15(d)(3)(ii)	1	1	1	2	2		
900.18(c)	2	1	2	2	4		
900.18(e)	2	1	2	1	2		
900.21(b)	0.33	1	0.33	320	106	$30,000	$174
900.21(c)(2)	0.1	1	0.1	30	3		
900.22(h)	5	200	1,000	.083	83		
900.22(i)	2	1	2	30	60		$20
900.23	5	1	5	20	100		
900.24(a)	0.4	1	0.4	200	80		$42
900.24(a)(2)	0.15	1	0.15	100	15		$21
900.24(b)	1	1	1	30	30		
900.24(b)(1)	0.3	1	0.3	200	60		$42
900.24(b)(3)	0.15	1	0.15	100	15		$21
900.25(a)	0.2	1	0.2	16	3.2		
FDA Form 3422	700	1	700	.25	175		
Total					3,620,692	$40,000	$19,768,361

[1] One-time burden.
[2] Refers to accreditation bodies applying to accredit specific Full Field Digital Mammography units.
[3] While not included in the 60-day notice, all 4 accreditation bodies are expected to reapply to continue to be accreditation bodies during the information collection period.
[4] Refers to the facility component of the burden for this requirement.
[5] Refers to the accreditation body component of the burden for this requirement.
[6] Refers to the situation where a patient specifically does not want to receive the lay summary of her exam.

TABLE 2—ESTIMATED ANNUAL RECORDKEEPING BURDEN

21 CFR Section	No. of Recordkeepers	Annual Frequency per Recordkeeping	Total Annual Records	Hours per Record	Total Hours	Total Capital Costs	Total Operating & Maintenance Costs
900.3(f)(1)	0.1	1	0.1	0	0		
900.4(g)	5	1	5	1	5		
900.12(a)(1)(i)(B)(2)	87	1	87	8	696		
900.12(a)(4)	8,681	4	34,724	1	34,724		
900.12(c)(4)	8,681	1	8,681	1	8,681	$28,000	
900.12(e)(13)	8,681	52	451,412	.083333	37,618		
900.12(f)	8,681	1	8,681	16	138,896		
900.12(h)(2)	8,681	2	17,362	1	17,362		
900.22(a)	5	1	5	1	5		
900.22(d)	5	1	5	1	5		
900.22(e)	5	1	5	1	5		
900.22(f)	3	1	3	1	3		
900.22(g)	5	1	5	1	5		$50
900.25(b)	5	1	5	1	5		
Total					238,010	$28,000	$50

Dated: May 27, 2010.

Leslie Kux,

Acting Assistant Commissioner for Policy.

[FR Doc. 2010–14317 Filed 6–14–10; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2010–N–0001]

Tobacco Product Constituents Subcommittee of the Tobacco Products Scientific Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Tobacco Product Constituents Subcommittee of the Tobacco Products Scientific Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on July 7, 2010, from 8:30 a.m. to 5 p.m. and on July 8, 2010, from 8 a.m. to 5 p.m.

Location: Hilton Washington DC North/Gaithersburg, Montgomery Ballroom, 620 Perry Pkwy., Gaithersburg, MD 20877. The hotel phone number is 301–977–8900.

Contact Person: Karen Templeton-Somers, Office of Science, Center for Tobacco Products, Food and Drug Administration, 9200 Corporate Blvd., Rockville, MD 20850, 1–877–287–1373 (choose Option 4), e-mail: *TPSAC@fda.hhs.gov* or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 8732110002. Please call the Information Line for up-to-date information on this meeting. A notice in the **Federal Register** about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency's Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.

Agenda: On July 7 and 8, 2010, the subcommittee will continue discussions, as needed, from the June 8 and 9, 2010, meeting of this subcommittee. The subcommittee will then receive presentations and discuss the analytic methods and ancillary and normalization standards applicable to the measurement and reporting of harmful or potentially harmful constituents in tobacco products, including smoke constituents. The subcommittee will finalize its proposed list of harmful or potentially harmful constituents, the rational for inclusion of each substance, validated methods for measuring the constituents and the ancillary and normalization standards for the identified constituents for presentation at a future meeting of the Tobacco Products Scientific Advisory Committee.

FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA's Web site after the meeting. Background material is available at *http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm*. Scroll down to the appropriate advisory committee link.